Literature DB >> 8088715

Castleman's disease. Differences in follicular dendritic network in the hyaline vascular and plasma cell variants.

D T Nguyen1, L W Diamond, M L Hansmann, M J Alavaikko, H Schröder, C Fellbaum, R Fischer.   

Abstract

Twenty-seven cases of the hyaline vascular variant and 10 cases of the plasma cell variant of Castleman's disease were studied with the paraffin resistant monoclonal antibodies Ki-FDC1p and/or Ki-M4p against follicular dendritic cells. Studies with the monoclonal antibody Ki-M9, for the detection of sinus lining cells, were also performed on the available frozen tissue in four cases of the hyaline vascular variant. In nine of the 10 plasma cell variant cases, the predominant type of follicular dendritic cell network was similar to that seen in normal or reactive germinal centres. In contrast, the hyaline vascular variant demonstrated either an expanded, disrupted, follicular dendritic cell network (10 cases) or multiple tight collections of follicular dendritic cells (16 cases). Sinus lining cells were not detected in the four cases studied. The difference in the predominant type of dendritic meshwork is an additional distinguishing feature to separate the plasma cell and hyaline vascular variants of Castleman's disease. The patterns of dendritic network seen in the hyaline vascular type, together with the absence of sinus lining cells, appear to favour the hamartoma theory proposed for this variant.

Entities:  

Mesh:

Year:  1994        PMID: 8088715     DOI: 10.1111/j.1365-2559.1994.tb00552.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  10 in total

1.  Lymphoid hyperplasia of the thymus showing Castleman's disease in a patient with myasthenia gravis.

Authors:  Masaru Kojima; Kazuhiko Shimizu; Yuko Kaneko; Nobuhide Masawa; Naoya Nakamura
Journal:  Rheumatol Int       Date:  2011-09-27       Impact factor: 2.631

2.  Castleman's disease of the spleen.

Authors:  Hee-Jeong Lee; Ho-Jong Jeon; Sang-Gon Park; Chi-Young Park
Journal:  World J Gastroenterol       Date:  2015-02-07       Impact factor: 5.742

Review 3.  [Diagnostic spectrum of reactive lymph node changes].

Authors:  S Hartmann; S Kriener; M L Hansmann
Journal:  Pathologe       Date:  2008-07       Impact factor: 1.011

Review 4.  Clinical features and outcome of patients with HIV-negative multicentric Castleman's disease treated with combination chemotherapy: a report on 10 patients.

Authors:  Shou-Hui Zhu; Yong-Hua Yu; Yong Zhang; Ju-Jie Sun; Da-Li Han; Jia Li
Journal:  Med Oncol       Date:  2013-02-12       Impact factor: 3.064

5.  Histomorphologic Spectrum in Hyaline Vascular Variant of Castleman Disease.

Authors:  Chaithra Gowthuvalli Venkataramana; Hema Kini; Debarshi Saha; Sharada Rai; Deepa Sowkur Anandarama Adiga; Ranjitha Rao; Cheryl Sarah Philipose
Journal:  J Clin Diagn Res       Date:  2017-08-01

6.  Cellular localisation of HHV-8 in Castleman's disease: is there a link with lymph node vascularity?

Authors:  J O'Leary; M Kennedy; D Howells; I Silva; V Uhlmann; K Luttich; S Biddolph; S Lucas; J Russell; N Bermingham; M O'Donovan; M Ring; C Kenny; M Sweeney; O Sheils; C Martin; S Picton; K Gatter
Journal:  Mol Pathol       Date:  2000-04

Review 7.  Castleman's disease--a two compartment model of HHV8 infection.

Authors:  Klaus-Martin Schulte; Nadia Talat
Journal:  Nat Rev Clin Oncol       Date:  2010-07-06       Impact factor: 66.675

8.  Castleman disease.

Authors:  Ibrahiem Saeed-Abdul-Rahman; Ali M Al-Amri
Journal:  Korean J Hematol       Date:  2012-09-25

9.  Successful Treatment of Mediastinal Unicentric Castleman's Disease Using Video-Assisted Thoracoscopic Surgery with Preoperative Embolization.

Authors:  Yosuke Amano; Daiya Takai; Nobuya Ohishi; Aya Shinozaki-Ushiku; Masashi Fukayama; Masaaki Akahane; Jun Nakajima; Takahide Nagase
Journal:  Case Rep Med       Date:  2013-09-30

10.  Establishment of a combination scoring method for diagnosis of ocular adnexal lymphoproliferative disease.

Authors:  Xiao-Li Qu; Yan Hei; Li Kang; Xin-Ji Yang; Yi Wang; Xiao-Zhong Lu; Li-Hua Xiao; Guang Yang
Journal:  PLoS One       Date:  2017-05-16       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.